This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

## Immune Globulins

**CG DRUG 09, DRUG.00013**

### Override(s) | Approval Duration
---|---
Prior Authorization | 1 year

### Medications | Quantity Limit

#### Intravenous:

<table>
<thead>
<tr>
<th>Medication</th>
<th>Quantity Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gamunex-C</td>
<td>Preferred</td>
</tr>
<tr>
<td>Octagam</td>
<td>Preferred</td>
</tr>
<tr>
<td>Bivigam</td>
<td>Non-Preferred</td>
</tr>
<tr>
<td>Carimune NF</td>
<td>Non-Preferred</td>
</tr>
<tr>
<td>Flebogamma DIF</td>
<td>Non-Preferred</td>
</tr>
<tr>
<td>Gammagard Liquid</td>
<td>Non-Preferred</td>
</tr>
<tr>
<td>Gammagard S/D less IgA</td>
<td>Non-Preferred</td>
</tr>
<tr>
<td>Gammaked</td>
<td>Non-Preferred</td>
</tr>
<tr>
<td>Gammaplex</td>
<td>Non-Preferred</td>
</tr>
<tr>
<td>Privigen</td>
<td>Non-Preferred</td>
</tr>
</tbody>
</table>

#### Subcutaneous:

<table>
<thead>
<tr>
<th>Medication</th>
<th>Quantity Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cuvitru</td>
<td>Non-Preferred</td>
</tr>
<tr>
<td>Hizentra</td>
<td>Non-Preferred</td>
</tr>
<tr>
<td>HyQvia</td>
<td>Non-Preferred</td>
</tr>
</tbody>
</table>

## APPROVAL CRITERIA

**Section 1:**

Requests for a non-preferred immune globulin (Ig) agent may be approved if I, II, III, IV, or V are met below in addition to one of the approvable diagnoses listed in **Section 2**:

I. Individual has had a trial of one preferred Ig agent; **OR**

II. The non-preferred agent is FDA approved for the prescribed indications, and preferred Ig agent is not FDA-approved for the prescribed indication; **OR**
Market Applicability/Effective Date

| Market | FL & FH | FL MMA | FL LTC | GA | KS | KY | LA | MD | NJ | NV | NY | TN | TX | WA |
|--------|--------|--------|--------|----|----|----|----|----|----|----|----|----|----|----|----|
| Applicable | X | NA | NA | X | NA | X | X | X | X | X | X | NA | NA | X |

*FHK- Florida Healthy Kids

III. The preferred Ig agent does not have an FDA or accepted off-label prescribed indication for use per the off-label policy criteria; OR

IV. The preferred Ig agent is not acceptable due to concomitant clinical condition(s), such as but not limited to the following:
   a. Renal insufficiency/impairment; OR
   b. Non-O blood type; OR
   c. Severe IgA deficiency; OR
   d. Diabetes/prediabetes; OR
   e. Cardiovascular disease; OR
   f. Hyper-prolinemia; OR
   g. Hypernatremia; OR
   h. Documented hypersensitivity, as manifested by a severe systemic/allergic or anaphylactic reaction, to any ingredient which is not also present in the requested non-preferred agent; OR
   i. Other known diseases state or medication contraindication which is not also associated with the requested non-preferred agent; OR
   j. High-risk for thrombosis, such as but not limited to:
      i. Hyperviscosity syndromes (such as cryoglobulinemia, monoclonal gammopathies, polyclonal hyperglobulinemia); OR
      ii. Hypercoagulable conditions; OR

V. Cuvitru, Hizentra or HyQvia [subcutaneous immune globulin (SCIG)] may be approved for individuals requesting for any of the following indications:
   a. Difficult vein access that precludes use of an intravenous immune globulin (IVIG); OR
   b. History of serious systemic reaction to IVIG expected to be avoided by using SCIG; OR
   c. History of inconsistent serum levels of immunoglobulin G (IgG) with IVIG.

Section 2:
Immune globulin (Ig) therapy may be approved for treatment of individuals with any of the indications:
   A. Antenatal alloimmune thrombocytopenia;
   B. Autoimmune mucocutaneous blistering diseases that are refractory, which include: pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane pemphigoid, and epidermolysis bullosa acquisita;
   C. Autoimmune Neutropenia;
   D. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
1. As an initial trial (up to 12 weeks) of Ig, when the medical record indicates that the clinical presentation is not consistent with other polyneuropathies (for example, IgM neuropathy, hereditary neuropathy, diabetic neuropathy) and ONE of the following clinical and electrodiagnostic criteria are met:
   a. There is proximal muscle weakness or sensory dysfunction caused by neuropathy and nerve conduction studies (NCS) confirm there is electrodiagnostic evidence of a demyelinating neuropathy in at least two limbs; OR
   b. There is distal muscle weakness and results of diagnostic testing meet a recognized set of diagnostic criteria as established by the American Academy of Neurology (AAN), or Inflammatory Neuropathy Cause and Treatment (INCAT).

2. As continued use of Ig after initial trial for CIDP when the following criteria are met:
   a. Clinically significant improvement in neurological symptoms is documented on physical examination; AND
   b. Continued need is demonstrated by documentation that attempts on an annual basis to titrate the dose or the interval of therapy result in worsening of symptoms

E. Dermatomyositis, refractory; (IVIG is used as a second line treatment of dermatomyositis. Corticosteroids are first-line treatments of dermatomyositis.);
F. Eaton- Lambert myasthenic syndrome treatment;
G. Guillain-Barre Syndrome (acute demyelinating polyneuropathy) as an equivalent alternative to plasma exchange;
H. Human immunodeficiency virus (HIV)-infected children – prevention of opportunistic bacterial infections;
I. Hyperimmunoglobulinemia E syndrome (HIE) treatment;
J. Hypogammaglobulinemia and recurrent bacterial infection associated with B-cell chronic lymphocytic leukemia (CLL) that includes both:
   1. Documented history of recurrent bacterial infection or an active infection not responding to antimicrobial therapy; AND
   2. Documentation that total IgG is less than 500 mg/dl
K. IgG sub-class deficiency (IgG1, IgG2, IgG3, IgG4) when the following are met:
   1. One or more serum IgG subclasses are below the lower limit of the age adjusted laboratory reference range or are more than two standard deviations below the age adjusted mean; AND
   2. History of recurrent sinopulmonary infections requiring antibiotic therapy; AND
   3. Lack of, or inadequate response to immunization (for example, but not limited to pneumococcal antigen)
L. Immune thrombocytopenia (idiopathic thrombocytopenic purpura [ITP]) in individuals with either of the following:

---

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.
This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

| Market | FL & FHK | FL MMA | FL LTC | GA | KS | KY | LA | MD | NJ | NV | NY | TN | TX | WA |
|--------|----------|--------|--------|----|----|----|----|----|----|----|----|----|----|----|----|
| Applicable | X | NA | NA | X | NA | X | X | X | X | X | X | NA | NA | X |

*FHK - Florida Healthy Kids

1. Symptomatic thrombocytopenia (for example, but not limited to hematuria, petechiae, bruising, gastrointestinal bleeding, gingival bleeding); OR
2. Platelet count less than 20,000 per microliter (mcL) (adult) or 30,000 mcL (child)

M. Kawasaki Syndrome:
1. Within 10 days of onset; AND
2. Treatment for no more than 5 days

N. Multifocal Motor Neuropathy (MMN) for either of the following:
1. As an initial trial (up to 4 weeks) to treat MMN, when ONE of the following criteria are met:
   a. There is asymmetric weakness that predominantly affects distal muscles (without upper motor neuron signs) AND nerve conduction studies confirm a demyelinating neuropathy is present (conduction block, slowing, or abnormal temporal dispersion in at least one nerve); OR
   b. Clinical history and exam do not suggest upper motor neuron disease (no bulbar weakness, no upper motor neuron signs) and labs show that GM-1 antibody titers are elevated; OR
   c. After the initial exam and electrodiagnostic testing clinical presentation suggests MMN but the diagnosis remains uncertain
2. Continued use of Ig after initial trial for MMN when the following criteria are met:
   a. Clinical results document an improvement in strength and function within three weeks of the start of the infusion period; AND
   b. Continued need is demonstrated by documentation that attempts on an annual basis to titrate the dose or the interval of therapy result in worsening of symptoms

O. Myasthenia Gravis, severe refractory;

P. Neonates - Prevention of infections in high-risk, preterm, low birth weight neonates;

Q. Parvovirus B19 chronic infection and severe anemia associated with bone marrow suppression;

R. Polymyositis; routine use of Ig is not recommended. Ig may be considered in individuals with severe polymyositis for whom other treatments have been unsuccessful, have become intolerable, or are contraindicated;

S. Primary humoral immunodeficiency - common variable immunodeficiency (CVID) when:
1. There is a history of recurrent sinopulmonary infections requiring antibiotic therapy; and
2. There is a lack of, or inadequate response to immunization (for example, but not limited to tetanus or pneumococcal antigen); and
3. There is no evidence of renal (nephrotic syndrome) and gastrointestinal (for example, protein losing enteropathy, PLE) as causes of hypogammaglobulinemia; and
4. The initial, pre-treatment total serum IgG is below the lower limit of the age adjusted laboratory reference range, or more than two standard deviations below the age adjusted mean.

T. Primary humoral immunodeficiency – Other (for example, congenital agammaglobulinemia, X-linked immunodeficiency, severe combined immunodeficiency [SCID], or Wiskott-Aldrich syndrome [WAS]) when:
   1. There is no evidence of renal (nephrotic syndrome) and gastrointestinal (for example, protein losing enteropathy) as causes of hypogammaglobulinemia; and
   2. The initial, pre-treatment total serum IgG is below the lower limit of the age adjusted laboratory reference range, or more than two standard deviations below the age adjusted mean.

U. Stiff-person syndrome not controlled by other therapies;

V. Toxic shock syndrome caused by staphylococcal or streptococcal organisms refractory to several hours of aggressive therapy;

W. Transplantation when any of the following are met:
   1. Hematopoietic stem cell transplant for either of the following:
      a. Allogeneic bone marrow transplant (BMT) recipients, in the first 100 days after transplantation, to reduce the risk of graft-versus-host disease associated with interstitial pneumonia (infectious or idiopathic) and infections (cytomegalovirus infections, varicella-zoster virus infection, and recurrent bacterial infection); OR
      b. Secondary hypoglobulinemia in individuals who are immunosuppressed (for example status-post bone marrow transplant) and have a documented total IgG less than 500 mg/dl
   2. Solid organ transplantation for either of the following:
      a. Prior to medically necessary solid organ transplantation for suppression of panel reactive anti-HLA antibodies in individuals with high panel reactive antibody (PRA) levels to human leukocyte antigens (HLA); OR
      b. Transplant recipients at risk for CMV;

Immune Globulin may NOT be approved for the following:
A. For the indications listed above when criteria are not met.
B. For all other indications not listed above, including but not limited to:
   1. Multiple sclerosis;
   2. Immune optic neuropathy;
This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

**Note:** Intravenous immunoglobulins have black box warnings for renal dysfunction, acute renal failure, osmotic nephrosis, and death. Use caution in individuals predisposed to acute renal failure and administer at the minimum concentration available and the minimum rate of infusion practicable in such individuals. Higher rates of renal failure were associated with IGIV products containing sucrose. Carimune NF is currently the only available agent on the market containing sucrose.

### Market Applicability/Effective Date

<table>
<thead>
<tr>
<th>Market</th>
<th>FL &amp; FHK</th>
<th>FL MMA</th>
<th>FL LTC</th>
<th>GA</th>
<th>KS</th>
<th>KY</th>
<th>LA</th>
<th>MD</th>
<th>NJ</th>
<th>NV</th>
<th>NY</th>
<th>TN</th>
<th>TX</th>
<th>WA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applicable</td>
<td>X</td>
<td>NA</td>
<td>NA</td>
<td>X</td>
<td>NA</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>NA</td>
<td>NA</td>
<td>X</td>
</tr>
</tbody>
</table>

*FHK- Florida Healthy Kids

### State Specific Mandates

| N/A | N/A | N/A |

### Key References: